Pasithea Therapeutics Corp. (KTTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pasithea Therapeutics Corp. on November 26, 2024. The Company, a Delaware corporation and emerging growth company, is reporting the entry into a material definitive agreement to facilitate the sale of its common stock.
Key Financial Metrics and Transaction Details
The filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to the new financing arrangement:
- Agreement Type: At The Market (ATM) Offering Agreement.
- Counterparty: H.C. Wainwright & Co., LLC (Sales Agent).
- Securities Eligible for Sale: Common Stock, par value $0.0001 per share.
- Aggregate Market Value Eligible: $2,076,000 (based on Form S-3 limitations).
- Commission Rate: 3.0% of the gross sales price of shares sold.
- Expense Reimbursement: Up to $100,000 for legal fees; $5,000 per due diligence session for 10-K filings; $3,500 per session for 10-Q/8-K filings.
Material Changes
The material change reported is the execution of the ATM Agreement on November 26, 2024. This agreement enables the Company to sell shares of common stock from time to time through the Sales Agent, subject to parameters set by the Company regarding share count, timing, daily limits, and minimum price. The Company retains the right to suspend offers at any time.
Outlook, Risks, and Management Commentary
Management has established a flexible mechanism to raise capital through the open market. The Sales Agent is not obligated to purchase shares on a principal basis. The offering will terminate upon the sale of all eligible shares or earlier termination by either party. The filing includes customary representations, warranties, and indemnification provisions. No specific guidance on future sales volume or timing was provided in this document.
Key Facts for Investor Verification
- Verify the current trading price of KTTA to assess the potential dilution impact of selling up to $2,076,000 worth of shares.
- Review the Company's most recent 10-Q or 10-K to understand current cash runway and liquidity needs driving this ATM agreement.
- Monitor future 8-K filings for actual sales activity under the ATM program and the total proceeds raised.
- Note that the Company is an emerging growth company, which may affect financial reporting standards.